Literature DB >> 31410753

Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.

Zhitao Dong1, Boyi Liao1, Weifeng Shen1, Chengjun Sui1, Jiamei Yang2.   

Abstract

BACKGROUND: Programmed death ligand 1 (PD-L1) is expressed in many malignancies and plays a critical role in escape from immune surveillance through inhibition of its receptor programmed death 1. The role of PD-L1 in intrahepatic cholangiocarcinoma (ICC) and mechanisms of its regulation, however, remain largely unknown. AIMS: To analyze the expression and prognostic significance of PD-L1 in ICC and to study the regulatory mechanisms of PD-L1.
METHODS: Samples were obtained from 125 patients diagnosed with ICC in the Eastern Hepatobiliary Surgery Hospital from January 2012 to January 2013. The records of each patient were analyzed to examine the relationship between PD-L1 and clinical data. In vitro experiments were performed to investigate the relationship between PD-L1 and the IL-6/mTOR signaling pathway and the feedback mechanism pathway of PD-L1.
RESULTS: Expression of PD-L1 is closely related to tumor vascular invasion, lymphatic metastasis and TNM staging. High PD-L1 expression is closely related to poor prognosis in ICC. Mechanically, IL-6 induces PD-L1 expression through mTOR signaling in ICC cells. In addition, PD-L1 has a negative feedback inhibition effect on AKT signaling.
CONCLUSIONS: In summary, high PD-L1 expression was found to be associated with poor prognosis. The IL-6/mTOR pathway upregulates expression of PD-L1, thus promoting tumor invasion, and PD-L1 negatively inhibits the AKT pathway.

Entities:  

Keywords:  B7-H1 antigen/CD274 protein, human; Cholangiocarcinoma, bile duct; Liver neoplasm; Prognosis; Signal transduction

Mesh:

Substances:

Year:  2019        PMID: 31410753     DOI: 10.1007/s10620-019-05787-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

Review 1.  Inhibitors of the PD-1 Pathway in Tumor Therapy.

Authors:  Martin W LaFleur; Yuki Muroyama; Charles G Drake; Arlene H Sharpe
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Dermatofibrosarcoma protuberans: A retrospective study of clinicopathologic features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1 expression.

Authors:  Sunyoung Park; Soyun Cho; Minji Kim; Ji Ung Park; Eui Cheol Jeong; Euno Choi; Jeong Hwan Park; Cheol Lee; Mee Soo Chang
Journal:  J Am Acad Dermatol       Date:  2018-05-22       Impact factor: 11.527

Review 3.  Regulation and Function of the PD-L1 Checkpoint.

Authors:  Chong Sun; Riccardo Mezzadra; Ton N Schumacher
Journal:  Immunity       Date:  2018-03-20       Impact factor: 31.745

4.  Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.

Authors:  Curtis A Clark; Harshita B Gupta; Gangadhara Sareddy; Srilakshmi Pandeswara; Shunhua Lao; Bin Yuan; Justin M Drerup; Alvaro Padron; José Conejo-Garcia; Kruthi Murthy; Yang Liu; Mary Jo Turk; Kathrin Thedieck; Vincent Hurez; Rong Li; Ratna Vadlamudi; Tyler J Curiel
Journal:  Cancer Res       Date:  2016-09-26       Impact factor: 12.701

5.  Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.

Authors:  Hirotake Tsukamoto; Koji Fujieda; Azusa Miyashita; Satoshi Fukushima; Tokunori Ikeda; Yosuke Kubo; Satoru Senju; Hironobu Ihn; Yasuharu Nishimura; Hiroyuki Oshiumi
Journal:  Cancer Res       Date:  2018-07-02       Impact factor: 12.701

6.  PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer.

Authors:  Lujun Chen; Yuqi Xiong; Jing Li; Xiao Zheng; Qi Zhou; Abbey Turner; Changping Wu; Binfeng Lu; Jingting Jiang
Journal:  Cell Physiol Biochem       Date:  2017-08-17

7.  Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses.

Authors:  Ying Zhu; Xiang-Yu Wang; Yu Zhang; Da Xu; Jian Dong; Ze Zhang; Chen-He Yi; Hu-Liang Jia; Xin Yang
Journal:  Cancer Manag Res       Date:  2018-10-02       Impact factor: 3.989

8.  PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer.

Authors:  Yang Wang; Tae Hyun Kim; Shamileh Fouladdel; Zhuo Zhang; Payal Soni; Angel Qin; Lili Zhao; Ebrahim Azizi; Theodore S Lawrence; Nithya Ramnath; Kyle C Cuneo; Sunitha Nagrath
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

Review 9.  Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.

Authors:  Alphonse E Sirica; Gregory J Gores; John D Groopman; Florin M Selaru; Mario Strazzabosco; Xin Wei Wang; Andrew X Zhu
Journal:  Hepatology       Date:  2019-03-25       Impact factor: 17.298

10.  Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.

Authors:  LiJun Xu; XiaoDong Chen; MingJing Shen; Dong-Rong Yang; Laifu Fang; Guobin Weng; Ying Tsai; Peter C Keng; Yuhchyau Chen; Soo Ok Lee
Journal:  Mol Oncol       Date:  2018-01-24       Impact factor: 6.603

View more
  7 in total

Review 1.  Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?

Authors:  María Gutiérrez-Larrañaga; Elena González-López; Adriel Roa-Bautista; Pedro M Rodrigues; Álvaro Díaz-González; Jesus M Banales; Marcos López-Hoyos; Alvaro Santos-Laso; Javier Crespo
Journal:  Liver Cancer       Date:  2021-09-21       Impact factor: 11.740

2.  Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis.

Authors:  Qinfen Xie; Lidong Wang; Shusen Zheng
Journal:  Dis Markers       Date:  2020-07-15       Impact factor: 3.434

3.  Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis.

Authors:  Changjiang Lei; Xiulan Peng; Xiaojun Gong; Ying Fan; Shenglin Wu; Ning Liu; Lei Li; Jianbin Huang; Gang Zheng; Zhixiong Long
Journal:  Aging (Albany NY)       Date:  2019-12-27       Impact factor: 5.682

4.  Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers.

Authors:  Jun Zhang; Zhenru Wu; Xin Zhang; Siyun Liu; Jian Zhao; Fang Yuan; Yujun Shi; Bin Song
Journal:  ESMO Open       Date:  2020-11

5.  Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma.

Authors:  Hong Wu; Yulong Wei; Mei Jian; Hong Lu; Qingzhu Song; Liheng Hao; Yong Yue
Journal:  Onco Targets Ther       Date:  2021-01-06       Impact factor: 4.147

6.  High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease.

Authors:  Sjoerd P F T Nota; Ahmad Al-Sukaini; Shalin S Patel; Francesco Sabbatino; G Petur Nielsen; Vikram Deshpande; Jennifer H Yearley; Soldano Ferrone; Xinhui Wang; Joseph H Schwab
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 5.738

7.  Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis.

Authors:  Limeng Wu; Canhua Jiang; Zhihui Zhu; Yao Sun; Tao Zhang
Journal:  PLoS One       Date:  2022-07-26       Impact factor: 3.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.